Search Results - "Tumeh, Paul"

The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade by Ribas, Antoni, Tumeh, Paul C

“…It is conceivable that, in the near future, an assay that defines the likelihood of a patient with advanced cancer to respond to immunotherapy based on PD1/L1…”
Get full text

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations by Shin, Daniel Sanghoon, Zaretsky, Jesse M, Escuin-Ordinas, Helena, Garcia-Diaz, Angel, Hu-Lieskovan, Siwen, Kalbasi, Anusha, Grasso, Catherine S, Hugo, Willy, Sandoval, Salemiz, Torrejon, Davis Y, Palaskas, Nicolaos, Rodriguez, Gabriel Abril, Parisi, Giulia, Azhdam, Ariel, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Berent-Maoz, Beata, Shintaku, I Peter, Le, Dung T, Pardoll, Drew M, Diaz, Jr, Luis A, Tumeh, Paul C, Graeber, Thomas G, Lo, Roger S, Comin-Anduix, Begoña, Ribas, Antoni

“…Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be…”
Get more information

PD-1 blockade induces responses by inhibiting adaptive immune resistance by Tumeh, Paul C., Harview, Christina L., Yearley, Jennifer H., Shintaku, I. Peter, Taylor, Emma J. M., Robert, Lidia, Chmielowski, Bartosz, Spasic, Marko, Henry, Gina, Ciobanu, Voicu, West, Alisha N., Carmona, Manuel, Kivork, Christine, Seja, Elizabeth, Cherry, Grace, Gutierrez, Antonio J., Grogan, Tristan R., Mateus, Christine, Tomasic, Gorana, Glaspy, John A., Emerson, Ryan O., Robins, Harlan, Pierce, Robert H., Elashoff, David A., Robert, Caroline, Ribas, Antoni

“…The dynamics of T-cell responses are investigated in tumour tissue from patients with advanced melanoma who were treated with a PD-1-blocking monoclonal…”
Get full text

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation by Mehta, Arnav, Kim, Yeon Joo, Robert, Lidia, Tsoi, Jennifer, Comin-Anduix, Begoña, Berent-Maoz, Beata, Cochran, Alistair J, Economou, James S, Tumeh, Paul C, Puig-Saus, Cristina, Ribas, Antoni

“…A promising arsenal of targeted and immunotherapy treatments for metastatic melanoma has emerged over the last decade. With these therapies, we now face new…”
Get more information

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma by Zaretsky, Jesse M, Garcia-Diaz, Angel, Shin, Daniel S, Escuin-Ordinas, Helena, Hugo, Willy, Hu-Lieskovan, Siwen, Torrejon, Davis Y, Abril-Rodriguez, Gabriel, Sandoval, Salemiz, Barthly, Lucas, Saco, Justin, Homet Moreno, Blanca, Mezzadra, Riccardo, Chmielowski, Bartosz, Ruchalski, Kathleen, Shintaku, I. Peter, Sanchez, Phillip J, Puig-Saus, Cristina, Cherry, Grace, Seja, Elizabeth, Kong, Xiangju, Pang, Jia, Berent-Maoz, Beata, Comin-Anduix, Begoña, Graeber, Thomas G, Tumeh, Paul C, Schumacher, Ton N.M, Lo, Roger S, Ribas, Antoni

“…Whole-exome sequencing was performed on four patients' tumors before exposure to pembrolizumab and after disease progression following a response to treatment…”
Get full text

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma by Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D, Hersey, Peter, Joseph, Richard W, Weber, Jeffrey S, Dronca, Roxana, Gangadhar, Tara C, Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M, Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C, Chmielowski, Bartosz, Ebbinghaus, Scot W, Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni

“…Antibodies to PD-1 appeared to unblock T-cell responses to melanoma in a sizeable fraction of patients with antitumor responses, some of which were…”
Get full text

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy by Reinhardt, Julia, Landsberg, Jennifer, Schmid-Burgk, Jonathan L, Ramis, Bartomeu Bibiloni, Bald, Tobias, Glodde, Nicole, Lopez-Ramos, Dorys, Young, Arabella, Ngiow, Shin Foong, Nettersheim, Daniel, Schorle, Hubert, Quast, Thomas, Kolanus, Waldemar, Schadendorf, Dirk, Long, Georgina V, Madore, Jason, Scolyer, Richard A, Ribas, Antoni, Smyth, Mark J, Tumeh, Paul C, Tüting, Thomas, Hölzel, Michael

“…Evolution of tumor cell phenotypes promotes heterogeneity and therapy resistance. Here we found that induction of CD73, the enzyme that generates…”
Get full text

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy by KOYA, Richard C, MOK, Stephen, RIBAS, Antoni, OTTE, Nicholas, BLACKETOR, Kevin J, COMIN-ANDUIX, Begonya, TUMEH, Paul C, MINASYAN, Aspram, GRAHAM, Nicholas A, GRAEBER, Thomas G, CHODON, Thinle

“…Combining immunotherapy with targeted therapy blocking oncogenic BRAFV600 may result in improved treatments for advanced melanoma. In this study, we developed…”
Get full text

PD-1 Blockade Expands Intratumoral Memory T Cells by Ribas, Antoni, Shin, Daniel Sanghoon, Zaretsky, Jesse, Frederiksen, Juliet, Cornish, Andrew, Avramis, Earl, Seja, Elizabeth, Kivork, Christine, Siebert, Janet, Kaplan-Lefko, Paula, Wang, Xiaoyan, Chmielowski, Bartosz, Glaspy, John A, Tumeh, Paul C, Chodon, Thinle, Pe'er, Dana, Comin-Anduix, Begoña

“…Tumor responses to programmed cell death protein 1 (PD-1) blockade therapy are mediated by T cells, which we characterized in 102 tumor biopsies obtained from…”
Get more information

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy by Nosrati, Adi, Tsai, Katy K, Goldinger, Simone M, Tumeh, Paul, Grimes, Barbara, Loo, Kimberly, Algazi, Alain P, Nguyen-Kim, Thi Dan Linh, Levesque, Mitchell, Dummer, Reinhard, Hamid, Omid, Daud, Adil

“…Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response…”
Get full text

Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 + T-cell Infiltration by Lee, Jay M, Lee, Mi-Heon, Garon, Edward, Goldman, Jonathan W, Salehi-Rad, Ramin, Baratelli, Felicita E, Schaue, Dörthe, Wang, Gerald, Rosen, Fran, Yanagawa, Jane, Walser, Tonya C, Lin, Ying, Park, Stacy J, Adams, Sharon, Marincola, Francesco M, Tumeh, Paul C, Abtin, Fereidoun, Suh, Robert, Reckamp, Karen L, Lee, Gina, Wallace, William D, Lee, Sarah, Zeng, Gang, Elashoff, David A, Sharma, Sherven, Dubinett, Steven M

“…A phase I study was conducted to determine safety, clinical efficacy, and antitumor immune responses in patients with advanced non-small cell lung carcinoma…”
Get full text

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC by Tumeh, Paul C, Hellmann, Matthew D, Hamid, Omid, Tsai, Katy K, Loo, Kimberly L, Gubens, Matthew A, Rosenblum, Michael, Harview, Christina L, Taube, Janis M, Handley, Nathan, Khurana, Neharika, Nosrati, Adi, Krummel, Matthew F, Tucker, Andrew, Sosa, Eduardo V, Sanchez, Phillip J, Banayan, Nooriel, Osorio, Juan C, Nguyen-Kim, Dan L, Chang, Jeremy, Shintaku, I Peter, Boasberg, Peter D, Taylor, Emma J, Munster, Pamela N, Algazi, Alain P, Chmielowski, Bartosz, Dummer, Reinhard, Grogan, Tristan R, Elashoff, David, Hwang, Jimmy, Goldinger, Simone M, Garon, Edward B, Pierce, Robert H, Daud, Adil

“…We explored the association between liver metastases, tumor CD8 T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1…”
Get more information

Characteristic purpura of the ears, vasculitis, and neutropenia–a potential public health epidemic associated with levamisole-adulterated cocaine by Chung, Catherine, MD, Tumeh, Paul C., MD, Birnbaum, Ron, MD, Tan, Belinda H., MD, PhD, Sharp, Linda, MD, McCoy, Erin, MD, Mercurio, Mary Gail, MD, Craft, Noah, MD, PhD, DTM&H

“…Background Dermatologists at the University of California, San Francisco recently reported two patients in the online Journal of the American Academy of…”
Get full text

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma by Nowicki, Theodore S, Akiyama, Ryan, Huang, Rong Rong, Shintaku, I Peter, Wang, Xiaoyan, Tumeh, Paul C, Singh, Arun, Chmielowski, Bartosz, Denny, Christopher, Federman, Noah, Ribas, Antoni

“…Tumors expressing programmed death ligand 1 (PD-L1) interact with the corresponding negative-signal generating immune receptor on the surface of CD8 T cells,…”
Get more information

Cancer therapy: Tumours switch to resist by Ribas, Antoni, Tumeh, Paul C

“…Tumour cells can respond to targeted immune-cell therapies by losing proteins that mark them as being cancerous. Subverting this resistance mechanism may lead…”
Get full text

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes by Robert, Lidia, Harview, Christina, Emerson, Ryan, Wang, Xiaoyan, Mok, Stephen, Homet, Blanca, Comin-Anduix, Begonya, Koya, Richard C, Robins, Harlan, Tumeh, Paul C, Ribas, Antoni

“…Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients. Our recent work revealed the immunological effects of…”
Get full text

Tumours switch to resist by Ribas, Antoni, Tumeh, Paul C.

“…Tumour cells can respond to targeted immune-cell therapies by losing proteins that mark them as being cancerous. Subverting this resistance mechanism may lead…”
Get full text

PET Imaging of Cancer Immunotherapy by Tumeh, Paul C, Radu, Caius G, Ribas, Antoni

“…Immune system activation can be elicited in viral infections, active immunization, or cancer immunotherapy, leading to the final common phenotype of increased…”
Get full text

Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review by Mesko, Shane, Konecny, Gottfried E, Tumeh, Paul C, Kamrava, Mitchell

“…Ipilimumab is a monoclonal cytotoxic T-lymphocyte-associated protein 4 antibody that has demonstrated improved survival in cutaneous melanoma. Little is known…”
Get full text

The Impact of Ex Vivo Clinical Grade Activation Protocols on Human T-cell Phenotype and Function for the Generation of Genetically Modified Cells for Adoptive Cell Transfer Therapy by TUMEH, Paul C, KOYA, Richard C, CHODON, Thinle, GRAHAM, Nicholas A, GRAEBER, Thomas G, COMIN-ANDUIX, Begoña, RIBAS, Antoni

“…Optimized conditions for the ex vivo activation, genetic manipulation, and expansion of human lymphocytes for adoptive cell therapy may lead to protocols that…”
Get full text